Italy could have AstraZeneca COVID-19 shots by end November, IRBM biotech says




  • In US
  • 2020-09-16 18:25:31Z
  • By Reuters

ROME (Reuters) - Italy could have its first shots of British drugmaker AstraZeneca's potential COVID-19 vaccine by the end of November, the managing director of IRBM told Reuters.

Biotech firm IRBM, whose lab is based south of Rome, is cooperating with AstraZeneca in developing a vaccine for the disease which has caused more than 35,600 deaths in Italy.

"It is possible to have the first shots in Italy by the end of November, provided the trial continues as planned and the vaccine is validated," Matteo Liguori said on Wednesday.

Italy's Health Minister had already said the vaccine could be available by the end of 2020.


(Reporting by Emilio Parodi; Writing by Angelo Amante; Editing by Alexander Smith)

COMMENTS

More Related News

Italy
Italy's 'Black Roosters' fight back as virus hit wine sales

Two days before the coronavirus pandemic shut down Italy for two months, shattering wine exports and sales, the owner of one of its most historic vineyards headed back into the country a worried man.

AstraZeneca says Tagrisso shown to slow lung cancer spreading to brain
AstraZeneca says Tagrisso shown to slow lung cancer spreading to brain
  • US
  • 2020-09-19 16:39:53Z

AstraZeneca's top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday. A study with patients diagnosed early enough for the lung tumour to be surgically removed, and who have a mutation of the so-called EGFR gene, found that Tagrisso cut the risk of developing brain metastases by 82%. The late-stage Phase III trial results - presented at the virtual European Society for Medical Oncology (ESMO) conference over the weekend - underscore the drug's potential and may encourage a push to diagnose lung cancer earlier for patients to benefit from the drug, Astra said.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US